Newsletter

 

 
www.senology.org  /  www.senology.it  Home Page

Literature Selection / Selezione della Letteratura

Editorial / Editoriale  

  • "Screening mammography in women 40 to 49 years of age" - Amir Qaseem, Department of Clinical Programs and Quality of Care, American College of Physicians, Philadelphia, PA, USA

    "The take home message is that we are recommending that physicians should periodically assess individual woman's risk of developing breast cancer and that screening mammography decisions be made on the basis of a conversation between women and their clinicians,. This conversation should address the woman's risk of breast cancer, her concerns and preferences about breast cancer and screening, and the benefits and harms of screening mammography. We want women to be fully informed about the benefits and risks from screening mammography, and to have the opportunity to participate in the decision to the extent they desire to. If a woman decides that the benefits outweigh the risks, we fully support her decision. If a woman decides that she wants to defer mammography, we recommend that she and her clinician re-address this decision every 1 to 2 years"
    (Comment on paper:Qaseem A et al.: "Screening mammography for women 40 to 49 years of age: a clinical practice guideline from the American College of Physicians", Ann Intern Med. 2007 Apr 3;146(7):511-5)

Press Releases / Comunicati Stampa  

News from Healthcare Companies / Notizie dalle Aziende

Web Sites / Siti Web Senologici

Calendar of Events / Prossimi Eventi Senologici

 



Literature Selection / Selezione della Letteratura

Editorial / Editoriale

"The majority of epidemiological studies demonstrate that use of oral contraceptives decreases the risk of epithelial ovarian carcinoma. However, there is no consensus regarding the effect of dose of estrogen and progestin components on risk.  In our population-based case-control study, we showed that oral contraceptives with low potency of estrogen and progestin components were at least as effective in reducing ovarian cancer risk as high potency formulations.  This study is unique in that a relatively large subset of women exclusively used oral contraceptive pills with norethindrone with no intra-individual variation in its dose. Among these women, using low doses of norethindrone was associated with significantly lower odds of developing ovarian carcinoma as compared to using high-dose norethindrone formulations (adjusted for estrogen dose). The fact that these low potency oral contraceptives reduce the risk of ovarian cancer is reassuring considering the present-day tendency to prescribe low-dose oral contraceptives. Future studies that include larger numbers of women are needed to further evaluate the association of low dose oral contraceptive formulations with ovarian cancer risk" . (Comment on paper:  Lurie G et al.: "Association of estrogen and progestin potency of oral contraceptives with ovarian carcinoma risk.
Obstet Gynecol. 2007r;109(3):597-607
)

Press Releases / Comunicati Stampa

 


Literature Selection / Selezione della Letteratura

 

Visitate periodicamente le sezioni "Senology News / Notizie flash in Senologia" e "Oncology News / Notizie flash in Oncologia" per conoscere in maniera tempestiva e concisa le novità internazionali in ambito senologico.ed oncologico

Accedete al Forum di discussione per eventuali osservazioni, note o commenti.

 

La Newsletter di Senology è inviata a tutti i gli utenti che sottoscrivono il  modulo di Iscrizione / Subscribe.
Per cancellare la sottoscrizione inviare un messaggio a  Cancella sottoscrizione / Unsubscribe
© A&B Edizioni Medico-Scientifiche. Tutti i diritti riservati